Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Redlich, Sandra ^a   Ribes, Sandra ^a   Schütze, Sandra ^a   Nau, Roland ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Sleep Laboratory   (Germany)

Author keywords

CNS infection; Escherichia coli; Palmitoylethanolamide; Phagocytosis

Indexed keywords

CXCL1 CHEMOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PALMIDROL; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; ENDOCANNABINOID; ETHANOLAMINE DERIVATIVE; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PALMITIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ENZYME RELEASE; ENZYME SYNTHESIS; ESCHERICHIA COLI; ESCHERICHIA COLI K1; IN VITRO STUDY; IN VIVO STUDY; INFECTION RESISTANCE; INTRACELLULAR KILLING; MACROPHAGE; MENINGOENCEPHALITIS; MICROGLIA; MOUSE; NEUROPROTECTION; NEWBORN; NONHUMAN; PHAGOCYTOSIS; SEPSIS; ANIMAL; BRAIN; C57BL MOUSE; CELL CULTURE; CEREBELLUM; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; METABOLISM; MICROBIOLOGY; NONPARAMETRIC TEST; PHYSIOLOGY; SPLEEN;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; CELLS, CULTURED; CEREBELLUM; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ETHANOLAMINES; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROGLIA; PALMITIC ACIDS; PHAGOCYTOSIS; PPAR ALPHA; SPLEEN; STATISTICS, NONPARAMETRIC;

EID: 84902066500     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-108     Document Type: Article

References (54)

1. Petrosino S, Iuvone T, Di Marzo V. N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities. Biochimie 2010, 92:724-727.
2. Coburn AF, Graham CE, Hahinger J. Effect of egg yolk in diets on anaphylactic arthritis (passive Arthus phenomenon) in the guinea pig. J Exp Med 1954, 100:425-435.
3. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by downmodulating mast cell activation. Eur J Pharmacol 1996, 300:227-236.
4. Calignano A, La RG, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394:277-281.
5. Lambert DM, Vandevoorde S, Diependaele G, Govaerts SJ, Robert AR. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 2001, 42:321-327.
6. Esposito E, Cuzzocrea S. Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. CNS Neurol Disord Drug Targets 2013, 12:55-61.
7. Esposito E, Impellizzeri D, Mazzon E, Paterniti I, Cuzzocrea S. Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. PLoS One 2012, 7:e41880.
8. Scuderi C, Steardo L. Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease. CNS Neurol Disord Drug Targets 2013, 12:62-69.
9. Facci L, Dal TR, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 1995, 92:3376-3380.
10. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 2002, 135:181-187.
11. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005, 67:15-19.
12. LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. Rapid broadspectrum analgesia through activation of peroxisome proliferatoractivated receptor-alpha. J. Pharmacol Exp Ther 2006, 319:1051-1061.
13. Carroll CB, Zeissler ML, Chadborn N, Gibson K, Williams G, Zajicek JP, Morrison KE, Hanemann CO. Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease. Neurochem Int 2011, 59:73-80.
14. De Petrocellis L, Davis JB, Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 2001, 506:253-256.
15. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007, 152:1092-1101.
16. Muccioli GG, Stella N. Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology 2008, 54:16-22.
17. Stella N, Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol 2001, 425:189-196.
18. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 2003, 23:7767-7775.
19. Redlich S, Ribes S, Schutze S, Czesnik D, Nau R. Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 and Streptococcus pneumoniae R6 by microglial cells. J Neuroimmunol 2012, 244:32-34.
20. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002, 15:95-110.
21. Ross RA, Brockie HC, Pertwee RG. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur J Pharmacol 2000, 401:121-130.
22. Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, Mor M, Russo R, Maccarrone M, Antonietti F, Duranti A, Tontini A, Cuzzocrea S, Tarzia G, Piomelli D. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A 2009, 106:20966-20971.
23. Rašková H, Mašek K, Linèt O. Non-specific resistance induced by palmitoylethanolamide. Toxicon 1972, 10:485-490.
24. Mašek K, Perlík F, Klíma J, Kahlich R. Prophylactic efficacy of N-2- hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. Eur J Clin Pharmacol 1974, 7:415-419.
25. Plesník V, Havrlantová M, Jancová J, Januska J, Macková O. Impulsin in the prevention of acute respiratory diseases in school children. Cesk Pediatr 1977, 6:365-369.
26. Cabellos C, Verdaguer R, Olmo M, Fernández-Sabe N, Cisnal M, Ariza J, Gudiol F, Viladrich PF. Community-acquired bacterial meningitis in elderly patients: experience over 30 years. Medicine (Baltimore) 2009, 88:115-119.
27. Gaschignard J, Levy C, Romain O, Cohen R, Bingen E, Aujard Y, Boileau P. Neonatal bacterial meningitis: 444 cases in 7 years. Pediatr Infect Dis J 2011, 30:212-217.
28. Weinberger B, Grubeck-Loebenstein B. Vaccines for the elderly. Clin Microbiol Infect 2012, 18(Suppl 5):100-108.
29. Talati AJ, Kim HJ, Kim YI, Yi AK, English BK. Role of bacterial DNA in macrophage activation by group B streptococci. Microbes Infect 2008, 10:1106-1113.
30. Ribes S, Ebert S, Regen T, Agarwal A, Tauber SC, Czenik D, Spreer A, Bunkowski S, Eiffert H, Hanisch UK, Hammerschmidt S, Nau R. Toll-like receptor stimulation enhances phagocytosis and intracellular killing of nonencapsulated and encapsulated Streptococcus pneumoniae by murine microglia. Infect Immun 2010, 78:865-871.
31. Ribes S, Ebert S, Czesnik D, Regen T, Zeug A, Bunkowski S, Mildner A, Eiffert H, Hanisch UK, Hammerschmidt S, Nau R. Toll-like receptor prestimulation increases phagocytosis of Escherichia coli DH5alpha and Escherichia coli K1 strains by murine microglial cells. Infect Immun 2009, 77:557-564.
32. Redlich S, Ribes S, Schutze S, Eiffert H, Nau R. Toll-like receptor stimulation increases phagocytosis of Cryptococcus neoformans by microglial cells. J Neuroinflammation 2013, 10:71.
33. Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 1998, 161:2428-2434.
34. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol 2000, 165:4537-4543.
35. Miyagi K, Kawakami K, Kinjo Y, Uezu U, Yamashiro S, Arakaki K. CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-gamma production by CD4+ T cells. Clin Exp Immunol 2005, 140:220-229.
36. Ribes S, Adam N, Schutze S, Regen T, Redlich S, Janova H, Borisch A, Hanisch UK, Nau R. The nucleotide-binding oligomerization domain-containing-2 ligand muramyl dipeptide enhances phagocytosis and intracellular killing of Escherichia coli K1 by Toll-like receptor agonists in microglial cells. J Neuroimmunol 2012, 252:16-23.
37. Parant M, Parant F, Chedid L. Enhancement of the neonate's nonspecific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant. Proc Natl Acad Sci U S A 1978, 75:3395-3399.
38. Fraser-Smith EB, Matthews TR. Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice. Infect Immun 1981, 34:676-683.
39. Sarkar K, Das PK. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines. J Immunol 1997, 158:5357-5365.
40. Krahenbuhl JL, Sharma SD, Ferraresi RW, Remington JS. Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice. Infect Immun 1981, 31:716-722.
41. Matsumoto K, Ogawa H, Nagase O, Kusama T, Azuma I. Stimulation of nonspecific host resistance to infection induced by muramyldipeptides. Microbiol Immunol 1981, 25:1047-1058.
42. Namba K, Nakajima R, Otani T, Azuma I. Oral application of romurtide, a synthetic muramyl dipeptide derivative, stimulates nonspecific resistance to microbial infections and hematopoiesis in mice. Vaccine 1996, 14:1149-1153.
43. Delarosa O, Dalemans W, Lombardo E. Toll-like receptors as modulators of mesenchymal stem cells. Front Immunol 2012, 3:182.
44. Ospelt C, Gay S. TLRs and chronic inflammation. Int J Biochem Cell Biol 2010, 42:495-505.
45. Iliev AI, Stringaris AK, Nau R, Neumann H. Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9). FASEB J 2004, 18:412-414.
46. Grandgirard D, Gaumann R, Coulibaly B, Dangy JP, Sie A, Junghanss T, Schudel H, Pluschke G, Leib SL. The causative pathogen determines the inflammatory profile in cerebrospinal fluid and outcome in patients with bacterial meningitis. Mediators Inflamm 2013, 2013:312476.
47. Nau R, Gerber J, Bunkowski S, Bruck W. Axonal injury, a neglected cause of CNS damage in bacterial meningitis. Neurology 2004, 62:509-511.
48. Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 2003, 4:103-112.
49. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010, 58:253-263.
50. Schutze S, Loleit T, Zeretzke M, Bunkowski S, Brück W, Ribes S, Nau R. Additive microglia-mediated neuronal injury caused by amyloid-beta and bacterial TLR agonists in murine neuron-microglia co-cultures quantified by an automated image analysis using cognition network technology. J Alzheimers Dis 2012, 31:651-657.
51. Nau R, Ribes S, Djukic M, Eiffert H. Strategies to increase the activity of microglia as efficient protectors of the brain against infections. Frontiers Cell Neurosci. 2014, 22:8-138.
52. Di PR, Impellizzeri D, Torre A, Mazzon E, Cappellani A, Faggio C, Esposito E, Trischitta F, Cuzzocrea S. Effects of palmitoylethanolamide on intestinal injury and inflammation caused by ischemia-reperfusion in mice. J Leukoc Biol 2012, 91:911-920.
53. Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS 2011, 8:4.
54. Keppel Hesselink JM, de Boer T, Witkamp RF. Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold. Int J Inflam. 2013, 2013:151028.